- Home
- ONC vs LYV Comparison
ONC vs LYV Comparison
Compare ONC & LYV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONC | LYV |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | Switzerland | United States |
| Employees | 12000 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4B | 36.8B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | ONC | LYV |
|---|---|---|
| Price | $294.00 | $158.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 21 |
| Target Price | ★ $385.10 | $182.38 |
| AVG Volume (30 Days) | 178.0K | ★ 2.4M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,201,406,000.00 |
| Revenue This Year | $723.76 | $10.24 |
| Revenue Next Year | $15.04 | $9.37 |
| P/E Ratio | $614.06 | ★ N/A |
| Revenue Growth | N/A | ★ 8.83 |
| 52 Week Low | $228.93 | $125.34 |
| 52 Week High | $385.22 | $175.25 |
Technical Indicators
Market Signals| Indicator | ONC | LYV |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 52.05 |
| Support Level | $283.56 | $151.57 |
| Resistance Level | $300.00 | $167.67 |
| Average True Range (ATR) | 6.64 | 5.03 |
| MACD | -2.11 | -0.15 |
| Stochastic Oscillator | 11.89 | 39.17 |
Price Performance
Historical ComparisonAbout ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
About LYV Live Nation Entertainment Inc.
Live Nation is the largest live entertainment company in the world, serving as a concert promoter, venue operator, and ticketing platform. In addition, the firm generates revenue from sponsorships and advertising. With offices in 51 countries, Live Nation promotes concerts globally and it owned, operated, or had exclusive booking rights to more than 400 venues worldwide at the end of 2025, which the firm says makes it the second-largest operator of music venues globally. In 2025, Live Nation promoted nearly 55,000 events, drawing roughly 160 million fans. Ticketmaster is a dominant global ticketing service, selling nearly 650 million tickets in 2025.